Podcasts

In this episode, hosts sit down with Robert Vigersky, MD, chief medical officer of Medtronic Diabetes, for a discussion around the MiniMed 780G, including use, exclusive features, and how patients can obtain the new system.

In this episode, Charles Wykoff, MD, PhD joins Dr. Sheth to provide insight into the recent landmark approval of pegcetacoplan injection (SYFOVRE™) for geographic atrophy, how clinical practice has changed as a result, and both the early struggles with and optimism for an ever-changing treatment landscape.

In this episode, hosts offer their reaction to topline data from the SURMOUNT-2 trial examining tirzepatide for weight management in T2D, the FDA's clearance of the Omnipod GO device, and results of the CLVer trial.

As part of our ARVO 2023 coverage, Dr. Sheth sat down with Pravin Dugel, MD, President of Iveric Bio to discuss avacincaptad pegol for geographic atrophy and a look back at Dr. Dugel's career and his transition into industry.

In the inaugural episode of "New Insight with Veeral Sheth, MD," Dr. Sheth speaks with Arshad Khanani, MD on exciting developments from 2022, and a look at both the conference and treatment landscape unfolding in 2023.

Our latest podcast offering is an in-depth dive into ophthalmology hosted by Dr. Sheth, featuring conversations with experts on the latest research, conference news, and daily practice.

In addition to sharing how a novel machine learning method may one day soon predict lung disease susceptibility, Kalhan describes the science behind the ALA Lung Health Cohort Research Study.

Cooke joins the first episode of 2023 to discuss his colleague’s specific role in lung cancer screening and intervention and advances to minimally invasive, robotic and bronchoscopic techniques.

The FDA has set a PDUFA date for daprodustat for February 1 for adult patients with chronic kidney disease.

Lawrence Eichenfield, MD, reviews major drug approvals and advancement of screening and prevention strategies for the youngest patients with atopic dermatitis.

As 2022 concludes, a dermatologist reflects on the first drug approved for vitiligo.

The American Lung Association ambassadors for tobacco cessation share best practices and their personal stories in this New Years resolution episode.

The pair of pulmonology and microbiology experts join the podcast to discuss what clinicians should look out for in indoor pollutant exposure risks, and how to manage their impact.

Will the complement C5 inhibitor drug receive FDA approval in 2023? Lally discusses this and more on the latest DocTalk.

The Pompe disease community is anticipating the pivotal FDA decision for AT-GAA, a combination therapy for late-onset Pompe disease (LOPD) that has the potential to expand the armamentarium of physicians.

A post-AAO 2022 discussion on avacincaptad pegol in GA and what this groundbreaking treatment represents in filling a currently unmet need.

Catherine Nester, RN, and Dr. Stephen Kingsmore, discuss the pivotal role of newborn screening in diagnosing rare diseases along with the impact that BeginNGS can have on the future of rare disease medicine.

Martha Gulati, MD, joins The Heart Team to share her professional experiences and recommendations in treating female-specific cardiovascular disease.

Simon Walsh, MD, and Elizabeth Estes join Lungcast to discuss advancements in biomarker and treatment option deliberation for the rare disease through data.

In this podcast episode, Jorge Plutzky, MD, and Michael Farkouh, MD, speak with University of Maryland's Matthew Weir, MD, about the growing involvement of renal care in modern heart disease patients.

The FDA approved esketamine in 2019 for major depressive disorder.

President and CSO of Odylia Therapeutics discusses the gene therapy pipeline, research and differences in operating as a nonprofit biotech company.

The Cleveland Clinic Director of Sleep Disorders Research navigates the complexities of OSA presentation, progression, management and eradication with the Lungcast team.

There are several early phase trials underway for new hepatitis B virus treatments.

Dr. David Rosmarin details the recent FDA approval of ruxolitinib cream for vitiligo and how the accessibility of the topical therapy could help the roughly one million patients in the US who can't access standard treatment.